Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMicrosalt Regulatory News (SALT)

Share Price Information for Microsalt (SALT)

Share Price is delayed by 15 minutes
Get Live Data
36.50    0.00 (0.00%)
Bid:
35.00
Ask:
38.00
Spread: 3.00 (8.571%)
Market Cap: £20.49m
SALT Live PriceLast checked at - London Stock Exchange

Intraday Microsalt Share Chart

H1 2025 Trading Update

18 Aug 2025 07:00

RNS Number : 6916V
MicroSalt PLC
18 August 2025
 

 

 

 

 

 

The information contained withing this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as incorporated into the laws of England and Wales by virtue of the European Union (Withdrawal) Act 2018 (as amended) and certain other enacting measures ("UK MAR"). With the publication of this announcement via a Regulatory Information service ("RIS"), this inside information is now considered to be in the public domain.

 

18 August 2025

MicroSalt plc

("MicroSalt" or the "Company")

 

 H1 2025 Trading Update

 

MicroSalt plc (AIM: SALT), a leading manufacturer of full-flavour natural salt with approximately 50% less sodium, is pleased to announce continuing advancement of its B2B bulk business during the six months ended 30 June 2025 ("H1 2025"). Furthermore, it has recently received increased North America volume projections from whom the Company describes as Customer 3, one of the world's largest food, soft drink and snack manufacturers.

 

While non-contractual, MicroSalt is confident in these volume projections which include a single new item, representing an addition to the Company's existing sales pipeline with Customer 3 and its divisions. The volume projections for this product (in North America only) indicate commencing rollout in Q2 2026 and resultant sales exceeding $5m in 2026 and expanding to $11m in 2027.

 

Meanwhile, the advancement of the Company's B2B bulk revenues continued during H1 2025. Total sales were a Company record of $0.9m in H1 2025, an increase of nearly $0.4m (c.72%) against H2 2024. Further, total H1 2025 sales represent 121% of sales for the entirety of 2024. This includes shipments to existing markets of Mexico, United States and Canada, as well as newly opened markets in the UK and Belgium.

 

Bulk sales in H1 2025 were dominated by repeat orders from different entities and geographies of Customer 3, and in particular:

· Customer 1 (Mexican division of Customer 3) purchased $0.6m for use in three mainstream items with two more planned to begin in Q3 or Q4 2025;

· Customer 2 (North American division of Customer 3 - Canada, US) purchased $0.2m for one full brand (multiple items) with two more planned for Q4 2025; and

· Non bulk sales to retail and ecommerce customers total $0.1m.

 

Microsalt Premium, initially targeting the quick service and fast service restaurant (QSR/FSR) market, has been expanded to include larger food service outlets, GPO's and school districts with a focus on readymade menu items. We continue to be in the final stages of consideration with a major fast-food company.

 

Gross cash as at 30 June 2025 was US$0.9m (31 December 2024: US$0.3m) following the fundraising of US$2.9m (before expenses) in February 2025. The key movement in H1 2025 was a $1.2m investment in inventory to meet expected much higher sales orders in H2 2025, albeit as detailed further below, there will be some delays in new product formulations due to the US FDA's focus on the elimination of petroleum-based food colourings alongside existing low sodium initiatives. Accordingly, H2 2025 cash utilisation will be much lower than that incurred in H1 2025.

 

Regulations globally continue to support the movement of healthier foods and lower sodium consumption. The unexpected focus by the US FDA on the elimination of petroleum-based food colouring has delayed the larger rollout from Q4 2025 into 2026 which has resulted in the Company adjusting its 2025 sales estimate to $2.0m (previously $2.5m) with a continuing acceleration through 2026 and 2027.

 

The Company is now projecting 2026 sales to total $6.7m based on in-hand volume estimations and its current customer base.

 

Rick Guiney, CEO of MicroSalt, said: "We are pleased with our H1 2025 sales results and continued scale up of our deployment with Customer 3 and its group. The robust sales pipeline and our ability to deliver consistent functionality across varied reformulation platforms underpins our confidence of future success."

 

 

For more information, please visit www.microsaltinc.co, follow on X @microSaltPLC or contact:

 

MicroSalt plc

c/o +44 (0)20 4582 3500

Rick Guiney, CEO 

Zeus (Nominated adviser and broker)

+44 (0)20 3829 5000

David Foreman, James Edis (Investment Banking)

Gracechurch Group (Financial PR)  

+44 (0)20 4582 3500

Heather Armstrong, Alexis Gore, Rebecca Scott

 

About MicroSalt®

 

MicroSalt® produces a patented full-flavour, low-sodium salt for food manufacturers and consumers.

 

MicroSalt is a major potential disruptor in the food market, thanks to its micron sized particles which deliver the same sense of saltiness to a wide range of foods but with approximately 50% less sodium. Excess sodium consumption is a significant contributor to cardiovascular disease and MicroSalt's solution meets the rising demand for healthier alternatives to traditional salt. The WHO has set a target for reducing global sodium intake by 30% by 2025, which it estimates will save 7 million lives by 2030.

 

Each year, cardiovascular disease costs the UK £19 billion - if the average salt intake was reduced by one gram per day, it has been estimated that 4,147 lives and £288 million would be saved each year in the UK. As a nation, the UK consumes 183 million kilograms of salt each year, and 70 per cent. of the typical person's sodium intake is hidden in processed foods.

 

Operational since 2018, MicroSalt uses patent-protected technology which helps create high barriers to entry within the reduced-sodium salt market. The group has a US patent and 14 patent applications pending in other jurisdictions globally.

 

The Directors believe that MicroSalt is well positioned to capture growth in the low sodium market, which is expected to grow exponentially, and that there is also potential to enter the larger salt market.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTGSGDISSBDGUI
12
Date   Source Headline
5th Jun 20267:00 amRNSNotice of AGM
28th May 20267:07 amRNSFinal Results
28th Apr 20267:00 amRNS-RMicroSalt Launches MicroSalt Fibre
5th Mar 20267:00 amRNS-RNew UK customer
2nd Mar 20267:00 amRNS-RMicroSalt Reaches One Billion Servings Milestone
13th Feb 20267:00 amRNSGrant of options and PDMR dealings
27th Jan 20267:25 amRNSSigned Joint Development Agreement
12th Jan 20267:00 amRNSTrading Update
15th Dec 20252:17 pmRNSAdmission, Director Dealings and TVR
12th Dec 20252:30 pmRNSResult of Retail Offer
9th Dec 20254:35 pmRNSLaunch of Retail Offer
9th Dec 20252:40 pmRNSSubscription to raise £1.5 million
21st Nov 20253:38 pmRNSExercise of Stock Options and Total Voting Rights
14th Nov 20257:00 amRNSTrading Update
12th Nov 20257:00 amRNSNew Strategic Relationship with Daiya Foods
30th Sep 20257:00 amRNSUnaudited Half-yearly Report
1st Sep 20257:00 amRNSBoard changes
18th Aug 20257:00 amRNSH1 2025 Trading Update
11th Aug 20257:00 amRNSMissed related party transaction
6th Aug 20257:38 amRNSRelated Party Transaction
27th Jun 20253:48 pmRNSResult of AGM
6th Jun 202512:30 pmRNSHolding(s) in Company
2nd Jun 20257:01 amRNSNotice of Investor Presentation 9th June 2025
2nd Jun 20257:00 amRNSFinal Results Year Ended 31 December Notice of AGM
24th Apr 20257:00 amRNSQ1 2025 Business Update
24th Mar 20257:00 amRNS-RIFE London Innovation in Nutritious Foods
19th Mar 20257:00 amRNS-RFast Award 2025
25th Feb 20257:00 amRNS-RTechnology of the Year 2025 Award
14th Feb 20251:22 pmRNSNotification of Major Holdings
14th Feb 20251:06 pmRNSNotification of Major Holdings
7th Feb 20257:00 amRNSFurther Re Fundraising
5th Feb 20257:00 amRNSExercise of Stock Options and Total Voting Rights
3rd Feb 20257:00 amRNSOversubscribed Fundraising of £2.3Million
16th Jan 20257:00 amRNS-RFDA Nutrition information on packaged foods
6th Jan 20254:51 pmRNSResults of General Meeting
10th Dec 20247:00 amRNSShareholder Circular and Notice of General Meeting
30th Oct 20247:00 amRNSNew and Follow-on B2B Customer Orders
18th Oct 20247:00 amRNSResponse to Share Price Movement
27th Sep 20247:00 amRNSMaiden Interim Results
16th Sep 20247:00 amRNSMultiple Placements of Products and B2B Progress
2nd Aug 20243:02 pmRNSNotification of Major Holdings
30th Jul 20247:00 amRNSExercise of Warrants and Total Voting Rights
16th Jul 20247:00 amRNSExercise Warrants PDMR Dealing Total Voting Rights
11th Jul 20247:00 amRNSExercise of Warrants and Total Voting Rights
2nd Jul 20243:31 pmRNSExercise of Warrants and Total Voting Rights
21st Jun 20243:17 pmRNSResult of AGM
17th Jun 202411:22 amRNSExercise Warrants PDMR Dealing Total Voting Rights
11th Jun 20247:00 amRNSExercise Warrants Options and Total Voting Rights
30th May 20247:20 amRNSFinal Year end Results and Notice of AGM
24th May 20244:18 pmRNSExercise of Warrants
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.